These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2274639)

  • 1. Cholecystokinin, dopamine and schizophrenia.
    Garver DL; Beinfeld MC; Yao JK
    Psychopharmacol Bull; 1990; 26(3):377-80. PubMed ID: 2274639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response.
    Beinfeld MC; Garver DL
    Prog Neuropsychopharmacol Biol Psychiatry; 1991; 15(5):601-9. PubMed ID: 1956989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine receptors and the dopamine hypothesis of schizophrenia.
    Seeman P
    Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine turnover in schizophrenia before and after haloperidol withdrawal. CSF, plasma, and urine studies.
    Beuger M; van Kammen DP; Kelley ME; Yao J
    Neuropsychopharmacology; 1996 Jul; 15(1):75-86. PubMed ID: 8797194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid zinc concentrations in ex-heroin addicts and patients with schizophrenia: some preliminary observations.
    Potkin SG; Shore D; Torrey EF; Weinberger DR; Gillin JC; Henkin RI; Agarwal RP; Wyatt RJ
    Biol Psychiatry; 1982 Nov; 17(11):1315-22. PubMed ID: 6129905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.
    Sedvall G
    Prog Biochem Pharmacol; 1980; 16():133-40. PubMed ID: 6160594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.
    Breslin NA; Suddath RL; Bissette G; Nemeroff CB; Lowrimore P; Weinberger DR
    Schizophr Res; 1994 Apr; 12(1):35-41. PubMed ID: 7517175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on dopamine metabolite in cerebrospinal fluid of schizophrenics and epilepsics].
    Jiang S; Chen X; Liao W
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(2):155-6. PubMed ID: 10681831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K; Tsuchida K; Kanzaki A; Ujike H; Hamamura T; Kondo K; Mutoh S; Miyanagi K; Kuroda S; Otsuki S
    Biol Psychiatry; 1995 Nov; 38(10):639-48. PubMed ID: 8555375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.
    Garver DL; Bissette G; Yao JK; Nemeroff CB
    Am J Psychiatry; 1991 Apr; 148(4):484-8. PubMed ID: 2006695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haloperidol induced CSF protein variations in schizophrenic patients: as studied by two-dimensional electrophoresis.
    Johnson G; Brane D; van Kammen DP; Gurklis J; Peters JL; Perel JM; Ghanbari HA; Merril CR
    Appl Theor Electrophor; 1992; 3(1):21-6. PubMed ID: 1599960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF dopamine turnover and positive schizophrenic symptoms after withdrawal of long-term neuroleptic treatment.
    Frecska E; Perényi A; Bagdy G; Révai K
    Psychiatry Res; 1985 Nov; 16(3):221-6. PubMed ID: 2868474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smooth pursuit eye movements, clinical symptoms, CSF metabolites, and skin conductance habituation in schizophrenic patients.
    Bartfai A; Levander SE; Sedvall G
    Biol Psychiatry; 1983 Sep; 18(9):971-87. PubMed ID: 6196060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low prolactin levels in cerebrospinal fluid: an after effect of lobotomy in chronic schizophrenia.
    Hyyppä MT; Liira J; Kampman R; Rimòn R
    Acta Psychiatr Belg; 1980; 80(4):452-7. PubMed ID: 7282416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma homovanillic acid as a predictor of response to neuroleptics.
    Davila R; Manero E; Zumarraga M; Andia I; Schweitzer JW; Friedhoff AJ
    Arch Gen Psychiatry; 1988 Jun; 45(6):564-7. PubMed ID: 3377643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium prevents adaptation of brain dopamine systems to haloperidol in schizophrenic patients.
    Sternberg DE; Bowers MB; Heninger GR; Charney DS
    Psychiatry Res; 1983 Oct; 10(2):79-86. PubMed ID: 6581492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication].
    Chen YF
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1984 Oct; 17(5):273-7. PubMed ID: 6085683
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.